Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tenax Therapeutics, Inc. (TENX)

0.29   0 (0%) 09-28 16:00
Open: 0.2986 Pre. Close: 0.29
High: 0.3008 Low: 0.284
Volume: 104,080 Market Cap: 7(M)

Technical analysis

as of: 2023-09-28 4:53:42 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 0.41     One year: 0.46
Support: Support1: 0.27    Support2: 0.23
Resistance: Resistance1: 0.35    Resistance2: 0.4
Pivot: 0.29
Moving Average: MA(5): 0.28     MA(20): 0.3
MA(100): 0.31     MA(250): 1.19
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.5     %D(3): 16.8
RSI: RSI(14): 44.8
52-week: High: 4.3  Low: 0.25
Average Vol(K): 3-Month: 526 (K)  10-Days: 180 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TENX ] has closed above bottom band by 42.4%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.3 - 0.3 0.3 - 0.3
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.29 - 0.29 0.29 - 0.29

Company Description

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Headline News

Fri, 25 Aug 2023
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole - InvestorPlace

Wed, 19 Jul 2023
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - Yahoo Finance

Fri, 23 Jun 2023
TENX: Notice of Allowance Increases Confidence - Yahoo Finance

Wed, 31 May 2023
5 Hot Penny Stocks To Watch With Big News This Week - Penny Stocks

Wed, 31 May 2023
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - Yahoo Finance

Wed, 12 Apr 2023
Tenax Therapeutics Provides 2023 Business Update - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 24 (M)
Shares Float 23 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 3.2 (%)
Shares Short 11 (K)
Shares Short P.Month 35 (K)

Stock Financials

EPS -3.12
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.55
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -46.1
Return on Equity (ttm) -79.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.35
Qtrly Earnings Growth 0
Operating Cash Flow -8 (M)
Levered Free Cash Flow -5 (M)

Stock Valuations

PE Ratio -0.1
PEG Ratio 0
Price to Book value 0.52
Price to Sales 0
Price to Cash Flow -0.84

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.